Arcus Biosciences, Inc.
RCUS
$24.90
$0.040.16%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 236.00M | 247.00M | 240.00M | 262.00M | 141.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 236.00M | 247.00M | 240.00M | 262.00M | 141.00M |
| Cost of Revenue | 523.00M | 523.00M | 503.00M | 485.00M | 461.00M |
| Gross Profit | -287.00M | -276.00M | -263.00M | -223.00M | -320.00M |
| SG&A Expenses | 111.00M | 110.00M | 112.00M | 115.00M | 116.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 634.00M | 633.00M | 615.00M | 600.00M | 577.00M |
| Operating Income | -398.00M | -386.00M | -375.00M | -338.00M | -436.00M |
| Income Before Tax | -369.00M | -353.00M | -340.00M | -297.00M | -390.00M |
| Income Tax Expenses | -- | -- | 1.00M | 1.00M | 1.00M |
| Earnings from Continuing Operations | -369.00 | -353.00 | -341.00 | -298.00 | -391.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -369.00M | -353.00M | -341.00M | -298.00M | -391.00M |
| EBIT | -398.00M | -386.00M | -375.00M | -338.00M | -436.00M |
| EBITDA | -389.00M | -376.00M | -365.00M | -328.00M | -426.00M |
| EPS Basic | -4.32 | -4.44 | -4.57 | -4.31 | -4.19 |
| Normalized Basic EPS | -1.99 | -2.06 | -2.14 | -1.97 | -2.61 |
| EPS Diluted | -4.32 | -4.44 | -4.57 | -4.31 | -4.19 |
| Normalized Diluted EPS | -1.99 | -2.06 | -2.14 | -1.97 | -2.61 |
| Average Basic Shares Outstanding | 456.50M | 429.50M | 402.70M | 387.60M | 372.60M |
| Average Diluted Shares Outstanding | 456.90M | 429.90M | 403.10M | 388.00M | 372.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |